Helsinn Group Launches Akynzeo Injection in US Market

Helsinn Group Launches Akynzeo Injection in US Market

By, Admin 27 June 2024

Overview

Helsinn Group, a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, announced that Akynzeo (fosnetupitant/palonosetron) injection is now available in the US in a ready-to-use vial.

About Akynzeo Injection

Akynzeo injection (ready-to-use) is a new method of administration and contains the same formulation as the prior Akynzeo injection (to-be-diluted).

Features

The features of the new ready-to-use presentation of Akynzeo injection include: 

  • No reconstitution or dilution required; 
  • Infuse directly from the vial using a built-in hanging strap; 
  • No refrigeration required at any point during distribution, storage, or preparation; 
  • Accessible via automated dispensing machine, allowing the product to be stored and available near the location of patient care.

Indication

  • Akynzeo injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. 
  • It has not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy. 
  • Akynzeo injection does not contain polysorbate 80 or allergenic excipients such as soy or egg lecithin. 
  • It can be administered simultaneously with intravenous dexamethasone sodium phosphate.

Words from CEO: Helsinn Group

Dr. Melanie Rolli, Helsinn Group CEO, commented: “As a pioneer in cancer supportive care, Helsinn continues to be unwavering in our pursuit to help patients and clinicians in cancer care. We are very pleased to launch the new Akynzeo ready-to-use vial, building on our legacy of innovation.”

To order New Vials

  • Clinicians wishing to order the new vial should contact their GPO or distributor. 
  • The National Drug Code (NDC) number for Akynzeo injection vial with hanger (Ready-to-Use) is 69639-106-01 and the J Code is J1454 (injection, fosnetupitant 235 mg and palonosetron 0.25 mg); billing unit (single dose vial [SDV]).

About Akynzeo

  • Akynzeo is the first and only 5-HT3 and NK1 receptor antagonists fixed combination approved for the prevention of chemotherapy-induced acute and delayed nausea and vomiting. 
  • A single dose of Akynzeo given with dexamethasone has been shown to prevent chemotherapy-induced nausea and vomiting for up to 5 days.

Akynzeo Indication

Akynzeo (fosnetupitant/palonosetron) injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.

Limitations of Use: 

Akynzeo injection has not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy.

Constituents of Akynzeo

Akynzeo is a combination of palonosetron, a serotonin-3 (5-HT3) receptor antagonist, and fosnetupitant, a substance P/neurokinin-1 (NK-1) receptor antagonist: palonosetron prevents nausea and vomiting during the acute phase and fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!